Table of Contents
ISRN Obstetrics and Gynecology
Volume 2011 (2011), Article ID 724649, 4 pages
http://dx.doi.org/10.5402/2011/724649
Review Article

Controversies in the Adjuvant Therapy of Endometrial Cancer

1Department of Obstetrics and Gynecology, Far Eastern Memorial Hospital, Banqiao, New Taipei 220, Taiwan
2Department of Obstetrics and Gynecology, National Taiwan University College of Medicine and National Taiwan University Hospital, Taipei 100, Taiwan
3Department of Oncology, National Taiwan University College of Medicine and National Taiwan University Hospital, Taipei 100, Taiwan

Received 26 June 2011; Accepted 2 August 2011

Academic Editors: M. A. Lumsden, A. Martin-Hidalgo, and Y. S. Song

Copyright © 2011 Sheng-Mou Hsiao and Lin-Hung Wei. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Endometrial cancer is the most common malignancy of the female genital tract. Surgical treatment includes hysterectomy, bilateral salpingo-oophorectomy, and an appropriate staging procedure. Relapse of endometrial cancer may occur in patients with high risk factors, such as old age, grade 3 cancer, deep myometrial invasion, and papillary serous and clear cell types. In recent years, several randomized trials reported the results of adjuvant therapy for patients with high risk factors. Nonetheless, some controversies still exist. This paper presents and discusses the results of important randomized trials of adjuvant therapy for endometrial cancer with risk factors.